Diana G. Mercurio, RPh, CDE, CDOE, CVDOE October 9, 2015



Similar documents
Type 2 Diabetes Medicines: What You Need to Know

Newer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013

Rx Updates New Guidelines, New Medications What You Need to Know

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Clinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives

ACUTE STROKE UNIT ORIENTATION

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Type 2 Diabetes Update For 2015

Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes

Anticoagulation Therapy Update

How To Treat Aneuricaagulation

DIABETES EDUCATION. *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions

Medicines for Type 2 Diabetes A Review of the Research for Adults

STROKE PREVENTION IN ATRIAL FIBRILLATION

New and Emerging Diabetes Medications. What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE

AFib (short for atrial fibrillation) is the most common type of irregular heartbeat, affecting literally millions of men and women

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Pharmaceutical Management of Diabetes Mellitus

Treatment of Type 2 Diabetes

Guidelines for Type 2 Diabetes Diagnosis

Cardiology Medications New Drugs, New Guidelines


STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

(TECHNICIANS) 4:30-5:30PM

Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians

Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs

COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.

Diabetes Fundamentals

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Let s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014

Targeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:

New Anticoagulants and GI bleeding

Atrial Fibrillation Centre

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

9/5/14. Objectives. Atrial Fibrillation (AF)

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

Novel OACs: How should we use them?"

The author has no disclosures

Antiplatelet and Antithrombotics From clinical trials to guidelines

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

TSOAC Initiation Checklist

Anticoagulants in Atrial Fibrillation

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Anticoagulants. Anticoagulants Definition. When are blood clots GOOD? Where and why do blood clots occur? 6/12/2014

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

Type 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action

How To Treat Diabetes

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

10/11/2014. Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014

Primary Care Type 2 Diabetes Update

Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR

Cardiovascular Risk in Diabetes

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

New Drug Update Joseph P. Vande Griend, PharmD, BCPS, CGP Associate Professor. Sunny Linnebur, Pharm.D., FCCP, BCPS, CGP Associate Professor

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Introduction. Background to this event. Raising awareness 09/11/2015

Blood-thinning medication after stroke

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

Introduction to Atrial Fibrillation (AFib)

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

CLINICAL GUIDELINE FOR SECONDARY PREVENTION AFTER STROKE OR TIA (PRIMARY AND SECONDARY CARE CORNWALL) MANAGEMENT 1. Aim/Purpose of this Guideline

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

Diabetes Medications. Minal Patel, PharmD, BCPS

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama

Causes, incidence, and risk factors

Main Effect of Screening for Coronary Artery Disease Using CT

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Type 2 Diabetes Medications: SGLT2 Inhibitors

Treatments to Restore Normal Rhythm

COLORADO MEDICAID P&T COMMITTEE MEETING MINUTES July 8, 2014

Stroke Care First week

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Harmony Clinical Trial Medical Media Factsheet

Transcription:

Diana G. Mercurio, RPh, CDE, CDOE, CVDOE October 9, 2015

I do not have any significant financial relationships to disclose.

Primary prevention: treatment of individuals with no history of stroke Secondary prevention: treatment of individuals who have already had a stroke or TIA

Treatment of modifiable risk factors: HTN Diabetes Dysplipidemia Atrial fibrillation Depression Smoking cessation Weight/body fat reduction Sickle cell disease Postmenopausal HRT

A- antiaggregants (ASA, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulation (warfarin, direct thrombin inhibitors and factor Xa inhibitors) B-Blood pressure-lowering medications C-Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization D-Diet E- Exercise Silver, Brian, MD, FRCPC, FAHA, FAAN Stroke Prevention http://emedicine.medscape.com/article/323662- overview

Define blood pressure control and choice of antihypertensive Identify advantages/disadvantages of novel anticoagulants vs. warfarin Review ACC/AHA guidelines for dysplipidemia treatment and treatment choices Identify blood glucose goals and describe new pharmacologic interventions Discuss pain after stroke and pharmacologic treatment options

According to the AHA/ASA, which of the interventions do you think is most important for the secondary prevention of ischemic stroke? A. Treatment of atrial fibrillation B. Control of high blood pressure C. Lower cholesterol D. Carotid revascularization

AHA/ASA: Hypertension most important intervention for secondary prevention of ischemic stroke Present in approx 70% of ischemic stroke Defined as SBP >140 mm Hg or DBP > 90mm Hg 23% reduction in stroke risk found with pharmacologic therapy

BP reduction more important than choice of agent; individualize therapy Three main classes for initial monotherapy: Thiazide diuretics (hydrochlorothiazide) ACE or ARB ( -pril, -arten) Long acting calcium channel blockers: amlodipine, felodipine, nifedipine

High blood pressure is asymptomatic Self-monitoring recommended Compliance with daily regimen necessary Take diuretics early in the morning Standing slowly risk of postural hypotension

Atrial Fibrillation 4-5 fold risk ischemic stroke Since 2010: 4 novel anticoagulants approved for stroke prevention in nonvalvular AF

Warfarin (Coumadin )-long history of benefit Gold Standard Effective stroke prevention in patients with AF Challenges: Food/drug interactions INR monitoring required Frequent dose changes confuse patients

New or novel anticoagulants Direct thrombin inhibitor: dabigatran (Pradaxa ) Factor Xa inhibitors: rivaroxaban (Xarelto ) apixaban (Eliquis ) edoxaban (Savaysa )

Advantages: No regular monitoring No known food interactions Rates of ICH lower = or superior to warfarin in stroke prevention Disadvantages: Not recommended with prosthetic valves Effect fades rapidly after last dose No specific antidote currently Cost

Adherence!! OTC drugs and herbal supplements may affect anticoagulant activity All health care providers need to be informed

Adult ACC/AHA Guideline released 2013 No reliance on cholesterol measurement to select drug therapy (no LDL-C target) Guidelines identify 4 statin benefit groups

1. Clinical ASCVD Coronary heart disease (ACS, MI, angina, coronary revascularization) Cerebral vascular disease (ischemic stroke, TIA) Peripheral vascular disease (PAD due to atherosclerosis) 2. LDL > 190 mg/dl 3. Age 40-75 with diabetes and LDL 70-189 mg/dl 4. Age 40-75 with LDL 70-189 mg/dl and 10-year ASCVD risk > 7.5%

Statins and diabetes Can cause mild glucose elevation in predisposed individuals. Tend to unmask underlying diabetes Statins and memory Very little evidence that statins impair memory function. In fact, research suggests that statins may help preserve memory by warding off strokes. Statins and muscles Severe muscle damage is exceedingly rare. Minor aches and pains are common yet often benign.

DM risk for first ischemic stroke No major trials for secondary prevention of stroke specifically examined interventions for pre-diabetes or DM Treatment goals: A1c < 7% FBG 80-130 mg/dl PPG <180 mg/dl

DPP-4 Inhibitors Sitagliptin (Januvia ), saxagliptin (Onglyza ), linagliptin (Tradjenta ), alogliptin (Nesina ) Improve A1c without causing hypoglycemia Prevent breakdown of GLP-1 GLP-1 blood glucose No weight gain Neutral or + effect on cholesterol

GLP-1 Receptor agonists exenatide (Byetta, Bydureon ) albiglutide (Tanzeum ) dulaglutide (Trulicity ) liraglutide (Victoza ) Mimic action of glucagon-like peptide 1 (GLP-1) Stimulate insulin secretion in response to rising blood sugar levels after a meal Delay movement of food from stomach to small intestine

SGLT2 (sodium-glucose transporter 2) Inhibitors SGLT2 works in the kidney to reabsorb glucose; by blocking this action excess glucose eliminated in the urine Side effects: UTIs; postural hypotension Canaglifozin (Invokana ), dapagliflozin (Farxiga )

Concentrated insulins: U-300 glargine (Toujeo ) U-200 lispro (Humalog ) Inhaled insulin (Afrezza ) rapid acting used in conjunction with long-acting not recommended in smokers

Central Pain Syndrome (Dejerine Roussy Syndrome) Originates in brain; not in peripheral nerves Occurs in up to 12% of post stroke patients Spasticity and Contractures Shoulder pain Frozen shoulder Subluxation

No cure Older antidepressants ( amitriptyline) pain, but cause sleepiness, dry mouth, dizziness Cymbalta, a newer antidepressant: useful, less side effects Antiepileptic drugs affect transmission of sensory nerves most common: gabapentin and pregabalin

Botox Blocks action of nerves on muscle, reducing muscle contraction Reduces muscle tone Injection only useful in small muscles, e.g. hand Baclofen (Lioresal ) Blocks action of nerves on muscle, reducing muscle contraction Side effects: confusion, hallucinations, slight sedation, loss of muscle tone or coordination and weakness in unaffected muscles Tizanidine (Zanaflex ) Reduces spasticity by blocking nerve impulses Short duration of action Side effects : hypotension, dry mouth, sleepiness

Benzodiazepine (diazepam, clonazepam) Relax muscles and spasticity briefly Act on central nervous system Side effects: drowsiness, muscle weakness, mental impairment Dantrolene (Dantrium ) Block signals for muscle contraction, muscle tone Side effects: depression, weakness, drowsiness, N/V, dizziness, diarrhea, and rarely liver failure

Non-steroidal anti-inflammatory drug (NSAID) Simple analgesics (acetaminophen,hydrocodone) Steroid injection Antispasmodics Non-pharmacologic interventions